X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (75) 75
humans (59) 59
52-week (50) 50
male (48) 48
female (37) 37
double-blind (34) 34
safety (28) 28
pharmacology & pharmacy (27) 27
middle aged (25) 25
diabetes mellitus, type 2 - drug therapy (24) 24
treatment outcome (24) 24
adult (23) 23
efficacy (23) 23
aged (22) 22
type 2 diabetes (21) 21
diabetes (20) 20
endocrinology & metabolism (19) 19
psychiatry (19) 19
52-week open-label (18) 18
business, finance (18) 18
hypoglycemic agents - administration & dosage (18) 18
studies (17) 17
52-week period (16) 16
animals (16) 16
asset pricing, trading volume, bond interest rates (16) 16
glucose (16) 16
52-week high (15) 15
hypoglycemic agents - therapeutic use (15) 15
stocks (15) 15
insulin glargine (14) 14
medicine, general & internal (14) 14
momentum (14) 14
partial recovery (14) 14
rats (14) 14
clinical trials (13) 13
double-blind method (13) 13
insulin (13) 13
open-label (13) 13
care and treatment (12) 12
diabetes mellitus, type 2 - blood (12) 12
insulin detemir (12) 12
neurotoxicity (12) 12
schizophrenia (12) 12
clinical neurology (11) 11
comparative analysis (11) 11
dermatology (11) 11
economics (11) 11
ecstasy (11) 11
hypoglycemic agents - adverse effects (11) 11
management (11) 11
neurosciences (11) 11
psoriasis (11) 11
risk (11) 11
body weight (10) 10
dose-response relationship, drug (10) 10
drug administration schedule (10) 10
information and market efficiency, event studies, insider trading (10) 10
diabetes mellitus (9) 9
hypoglycemia (9) 9
internal medicine (9) 9
metformin (9) 9
psoriasis - drug therapy (9) 9
returns (9) 9
serotonin (9) 9
severity of illness index (9) 9
trial (9) 9
type 2 diabetes mellitus (9) 9
52-week efficacy (8) 8
analysis (8) 8
blood glucose - drug effects (8) 8
detemir (8) 8
glargine (8) 8
glycemic control (8) 8
mdma (8) 8
medicine & public health (8) 8
underreaction (8) 8
young adult (8) 8
3,4-methylenedioxymethamphetamine mdma (7) 7
adolescent (7) 7
blood glucose - analysis (7) 7
brain (7) 7
drug therapy (7) 7
insulin, long-acting - administration & dosage (7) 7
medicine, research & experimental (7) 7
nutritional and metabolic diseases (7) 7
original (7) 7
paliperidone palmitate (7) 7
placebo-controlled trial (7) 7
serotonin - metabolism (7) 7
stock prices (7) 7
therapy (7) 7
time factors (7) 7
tolerability (7) 7
add-on (6) 6
antipsychotics (6) 6
basal-bolus regimen (6) 6
dextrose (6) 6
drug therapy, combination (6) 6
endocrine system diseases (6) 6
glipizide (6) 6
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (137) 137
Chinese (8) 8
Japanese (5) 5
German (2) 2
French (1) 1
Hungarian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Empirical Finance, ISSN 0927-5398, 09/2019, Volume 53, pp. 238 - 256
We show that when the disposition effect and anchoring bias of investors reinforce each other, the momentum profit is strengthened. When the two effects offset... 
52-Week High Anchoring Bias | Momentum | Disposition Effect | Stocks | Business schools
Journal Article
Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose | Index Medicus
Journal Article
Economic Modelling, ISSN 0264-9993, 07/2019
Journal Article
Finance Research Letters, ISSN 1544-6123, 06/2018, Volume 25, pp. 259 - 265
The superior performance of a momentum strategy long in stocks trading near their 52-week high prices and short in stocks trading far from their 52-week high... 
BUSINESS, FINANCE | PRICES | 52-WEEK | Stocks | Securities trading | Business schools
Journal Article
ANNALS OF PHARMACOTHERAPY, ISSN 1060-0280, 11/2014, Volume 48, Issue 11, pp. 1494 - 1501
Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of albiglutide, a glucagon-like peptide-I receptor agonist (GLP-I RA) in type 2... 
SAFETY | T2D | EXENATIDE | OPEN-LABEL | PHARMACODYNAMICS | MELLITUS | GLP-I receptor agonist | ONCE-WEEKLY ALBIGLUTIDE | albiglutide | 52-WEEK EFFICACY | PHARMACOKINETICS | LIRAGLUTIDE | TOLERABILITY | PHARMACOLOGY & PHARMACY
Journal Article
Journal of Financial Economics, ISSN 0304-405X, 04/2018, Volume 128, Issue 1, pp. 148 - 163
The Hou et al. (2015) q-factor model outperforms other factor models in capturing the price-to-high (PTH, the ratio of current price to 52-week high price)... 
q-factor model | Profitability | 52-week high | Anomalies | Investment growth | BUSINESS, FINANCE | PRICES | MOMENTUM | PREMIUM | ACCRUALS | RISK | ECONOMICS | Studies | Return on investment | CAPM
Journal Article
Journal of International Money and Finance, ISSN 0261-5606, 2011, Volume 30, Issue 1, pp. 180 - 204
We study the 52-week high momentum strategy in international stock markets proposed by George and Hwang [George, T., Hwang, C.Y., 2004. The 52-week high and... 
Momentum investing | International stock markets | 52-Week high | BUSINESS, FINANCE | COVARIANCE-MATRIX | BUSINESS-CYCLE | PROFITABILITY | RETURNS | SIZE | RISK | 52-Week high Momentum investing International stock markets | Stock markets | Transaction costs | Forecasts and trends | Studies | Investment policy | Securities markets | Profits | Macroeconomics | Indexes
Journal Article
Journal of Accounting, Auditing and Finance, ISSN 0148-558X, 2018, p. 148558
Journal Article
Journal of Financial Economics, ISSN 0304-405X, 05/2012, Volume 104, Issue 2, pp. 401 - 419
Motivated by psychological evidence on limited investor attention and anchoring, we propose two proxies for the degree to which traders under- and overreact to... 
Underreaction | Anchor | Attention | Overreaction | 52-week high | G12 | G14 | MOMENTUM | BEHAVIOR | EARNINGS | RISK | OVERREACT | BUSINESS, FINANCE | ECONOMICS | MARKET-EFFICIENCY | VOLATILITY | CONSUMPTION | REGRESSIONS | PROSPECT-THEORY | Monte Carlo method | Analysis | Psychological aspects | Studies | Securities trading | Rates of return | Monte Carlo simulation
Journal Article
Diabetes Care, ISSN 0149-5992, 10/2014, Volume 37, Issue 10, pp. 2723 - 2730
OBJECTIVE To evaluate weekly subcutaneous albiglutide versus daily sitagliptin in renally impaired patients with type 2 diabetes and inadequately controlled... 
52-WEEK EFFICACY | METFORMIN | GLYCEMIC CONTROL | PLACEBO | MANAGEMENT | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | WEIGHT-GAIN | PREVALENCE | MELLITUS | CHRONIC KIDNEY-DISEASE | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Diabetic Nephropathies - drug therapy | Male | Diabetic Nephropathies - blood | Hypoglycemic Agents - administration & dosage | Female | Renal Insufficiency - drug therapy | Sitagliptin Phosphate | Renal Insufficiency - blood | Diabetes Mellitus, Type 2 - complications | Receptors, Glucagon - agonists | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucagon-Like Peptide-1 Receptor | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Sitagliptin | Dosage and administration | Comparative analysis | Hyperglycemia | Exercise | Diabetes | Glucose | Diet | Medical treatment | Index Medicus
Journal Article
Journal Article
CURRENT MEDICAL RESEARCH AND OPINION, ISSN 0300-7995, 08/2015, Volume 31, Issue 8, pp. 1487 - 1493
Objective: Insulin degludec, a basal insulin with an ultra-long duration of action, became available in Sweden from July 2013. The diabetes team at Danderyd... 
MEDICINE, RESEARCH & EXPERIMENTAL | GLYCEMIC CONTROL | DETEMIR | BASAL-BOLUS REGIMEN | ADD-ON | ASPART | ANALOGS | OPEN-LABEL | Hypoglycemia | TRIAL | MEDICINE, GENERAL & INTERNAL | Basal-bolus | Basal insulin | GLARGINE | HbA(1c) | Type 1 diabetes | Outpatient | 52-WEEK | Insulin degludec
Journal Article
Pharmacopsychiatry, ISSN 0176-3679, 07/2017, Volume 50, Issue 4, pp. 145 - 151
Abstract Introduction The second generation long-acting antipsychotics can be a pharmacologic strategy, both in the early phase of illness and in the case of... 
Original Article | plasma level | Schizophrenia | paliperidone palmitate | long acting injectable | EFFICACY | SAFETY | PSYCHIATRY | 52-WEEK OPEN-LABEL | PALMITATE | MAINTENANCE THERAPY | ANTIPSYCHOTICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | OLANZAPINE
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 1/2018, Volume 53, Issue 1, pp. 140 - 151
We aimed to investigate the efficacy of canagliflozin (based on its effect on liver function and blood glucose levels) and its safety in high alanine... 
Medicine & Public Health | Canagliflozin | Colorectal Surgery | Hepatology | Japan | Gastroenterology | Abdominal Surgery | Alanine aminotransferase | Type 2 diabetes mellitus | Surgical Oncology | Hepatic function | VISCERAL FAT | EFFICACY | SAFETY | FATTY LIVER-DISEASE | 52-WEEK OPEN-LABEL | NONALCOHOLIC STEATOHEPATITIS | PREVALENCE | INSULIN-RESISTANCE | DOUBLE-BLIND | GASTROENTEROLOGY & HEPATOLOGY | ASSOCIATION | Canagliflozin - administration & dosage | Liver Function Tests | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Canagliflozin - pharmacology | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Body Weight - drug effects | Male | Canagliflozin - adverse effects | Hypoglycemic Agents - pharmacology | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Hypoglycemic Agents - administration & dosage | Sodium-Glucose Transporter 2 Inhibitors - administration & dosage | Adult | Female | Aged | Liver Diseases - drug therapy | Liver Diseases - physiopathology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Medical research | Blood sugar | Liver | Clinical trials | Glycosylated hemoglobin | Medicine, Experimental | Alanine | Diabetes mellitus | Body weight | Hemoglobin | Alanine transaminase | Glucose | Diabetes | Index Medicus
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 08/2019, Volume 46, Issue 8, pp. 686 - 694
Risankizumab, a humanized immunoglobulin G1 monoclonal antibody, selectively inhibits interleukin‐23, a key cytokine in the pathogenesis of psoriasis, by... 
interleukin‐23 | plaque psoriasis | psoriasis | Japanese patient | risankizumab | interleukin-23 | TO-SEVERE PSORIASIS | ADALIMUMAB | USTEKINUMAB | MONOCLONAL-ANTIBODY | IL-23 | DERMATOLOGY | PATHOGENESIS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | 52-WEEK | SKIN | Monoclonal antibodies | Product development | Arthritis | Interleukins | Clinical trials | Safety | Psoriasis | Immunoglobulin G | Index Medicus
Journal Article
Journal of Psychopharmacology, ISSN 0269-8811, 3/2016, Volume 30, Issue 3, pp. 242 - 252
Journal Article
Journal of Psychopharmacology, ISSN 0269-8811, 10/2018, Volume 32, Issue 10, pp. 1086 - 1097
Journal Article